Over the last 5 years, the emergence of gene expression profiling using high-density DNA microarrays led to a better understanding of tumor development and identified new prognostic markers. However, high-density microarrays failed to leap from the researcher's bench to the clinical practice due to their cost, data management and lack of standardization. DualChip® low-density DNA microarrays were developed as a new flexible tool that is able to reliably quantify the expression of a limited number of genes of clinical relevance. This review will illustrate how DualChip technology can be applied to tumor diagnosis and tumor-acquired drug resistance.
Gillet, J-P., De Longueville, F., & Remacle, J. (2006). DualChip® microarray as a new tool in cancer research. Expert Review of Molecular Diagnostics, 6(3), 295-306. https://doi.org/10.1586/14737220.127.116.115